Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing all-case surveillance of Empaveli in Japanese patients with paroxysmal nocturnal hemoglobinuria
jRCT2031230275Recruiting
- Sponsor
- Sobi
- Start
- Nov 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Sobi. Primary endpoints: Incidence of hypersensitivity reactions, Incidence of meningococcal infection and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031230275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230275.